JOHANNESBURG - Russia’s Sputnik V COVID-19 jab will not be used in South Africa.
The South African Health Products Regulatory Authority (SAHPRA) declined the application for its use, citing safety concerns.
SAHPRA says its research shows that the vaccine may increase the risk of contracting HIV for men.
The regulator says its request for data that demonstrate the safety and usage of the vaccine has not been addressed.
Meanwhile, the Gamaleya Center of Epidemiology and Microbiology told eNCA, "while SAPHRA's rolling review of Sputnik V continues, all the required information confirming that possible concerns about the safety of Ad5-vectored vaccines in populations at risk for HIV infection are completely unfounded will be submitted to the South African regulator”.
The Moscow-based Gamaleya Center of Epidemiology and Microbiology is involved in the development of Sputnik V COVID-19 vaccine.
The research centre also says there is no evidence of increased risk of HIV infection among the human population after common cold or conjunctivitis, and that there is no scientific or clinical evidence confirming the association of wild type adenoviruses or replicative defective adenovirus vectors with increased risk of HIV infection.
The centre says the scientific plausibility of this association is also unlikely.
The vaccine developed in Russia has been under review since February.